Mylan N.V. (MYL) is an interesting player in the Healthcare space, with a focus on Drugs – Generic. The stock has been active on the tape, currently trading at $39.18, up from yesterday’s close by 1.77%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Mylan N.V. (MYL) currently trades with a market capitalization of $19.31 Billion. That value represents a market adjusting for revenues that have been falling by -1.29 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $1.99 Billion over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.97 on a per share basis this quarter. Perhaps, that suggests something about why 0.63% of the outstanding share supply is held by institutional investors.
It’s important to check the technicals to get a sense of how MYL has been acting. Looking at the stock’s movement on the chart, Mylan N.V. recorded a 52-week high of $47.82. It is now trading 8.64% off that level. The stock is trading $39.87 its 50-day moving average by 0.69%. The stock carved out a 52-week low down at $29.39.
In recent action, Mylan N.V. (MYL) has made a move of -3.83% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.61, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.74% with $483.36 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of MYL.